Dosimetric study to assess the feasibility of intraoperative radiotherapy with electrons (ELIOT) as partial breast irradiation for patients with cardiac implantable electronic device (CIED)

Research output: Contribution to journalArticle

Abstract

Purpose: To report in-vivo dosimetry in the infraclavicular region, a potential site of a cardiac implantable electronic device (CIED) and to evaluate the absorbed dose from intraoperative radiotherapy with electrons (ELIOT). Methods: 27 non-cardiopathic breast cancer (BC) patients without CIED received quadrantectomy and ELIOT as partial breast irradiation. Before delivering ELIOT, two catheters, each containing eight thermoluminescent dosimeters (TLDs), were positioned in the infraclavicular region. TLDs internal catheter was located deep in the tumor bed while the external catheter was placed on patient’s skin. Results: Data were available for 24/27 patients. The absorbed doses were referred to the dose of 21 Gy. Values measured by the external catheter were low, although statistically significant higher doses were found close to the applicator (mean values 0.26–0.49 Gy). External TLD doses in proximity of the applicator were lower than those detected by their internal counterparts. Values measured by the internal catheter TLDs varied according to the distance from the applicator while no correlation with tumor site and beam energy was found. The distance from the applicator to deliver < 2 Gy to a CIED was 2 cm, while from 2.5 cm the dose measured in all the patients became negligible. Conclusions: This dosimetric study provided data to support the clinical use of ELIOT in BC patients having CIEDs as long as the suggested minimum safe distance of 2.5 cm is taken from the RT field in case of ELIOT single dose of 21 Gy, in the energy range of 6–10 MeV.

Original languageEnglish
Pages (from-to)693-699
Number of pages7
JournalBreast Cancer Research and Treatment
Volume171
Issue number3
DOIs
Publication statusPublished - Oct 1 2018

Fingerprint

Breast
Radiotherapy
Catheters
Electrons
Equipment and Supplies
Breast Neoplasms
Neoplasms
Skin
Radiation Dosimeters

Keywords

  • Breast cancer
  • Cardiac devices
  • In vivo dosimetry
  • Intraoperative radiotherapy
  • Thermoluminescent dosimeters

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{78ba6e8030b14e98a411f4de25b1f1b0,
title = "Dosimetric study to assess the feasibility of intraoperative radiotherapy with electrons (ELIOT) as partial breast irradiation for patients with cardiac implantable electronic device (CIED)",
abstract = "Purpose: To report in-vivo dosimetry in the infraclavicular region, a potential site of a cardiac implantable electronic device (CIED) and to evaluate the absorbed dose from intraoperative radiotherapy with electrons (ELIOT). Methods: 27 non-cardiopathic breast cancer (BC) patients without CIED received quadrantectomy and ELIOT as partial breast irradiation. Before delivering ELIOT, two catheters, each containing eight thermoluminescent dosimeters (TLDs), were positioned in the infraclavicular region. TLDs internal catheter was located deep in the tumor bed while the external catheter was placed on patient’s skin. Results: Data were available for 24/27 patients. The absorbed doses were referred to the dose of 21 Gy. Values measured by the external catheter were low, although statistically significant higher doses were found close to the applicator (mean values 0.26–0.49 Gy). External TLD doses in proximity of the applicator were lower than those detected by their internal counterparts. Values measured by the internal catheter TLDs varied according to the distance from the applicator while no correlation with tumor site and beam energy was found. The distance from the applicator to deliver < 2 Gy to a CIED was 2 cm, while from 2.5 cm the dose measured in all the patients became negligible. Conclusions: This dosimetric study provided data to support the clinical use of ELIOT in BC patients having CIEDs as long as the suggested minimum safe distance of 2.5 cm is taken from the RT field in case of ELIOT single dose of 21 Gy, in the energy range of 6–10 MeV.",
keywords = "Breast cancer, Cardiac devices, In vivo dosimetry, Intraoperative radiotherapy, Thermoluminescent dosimeters",
author = "Rosa Luraschi and Roberta Lazzari and Viviana Galimberti and Elena Rondi and Alessia Bazani and Giovanni Corso and Nicola Colombo and Rosalinda Ricotti and Cristiana Fodor and Mikolaj Winnicki and Leonardi, {Maria Cristina} and Jereczek-Fossa, {Barbara Alicja} and Federica Cattani",
year = "2018",
month = "10",
day = "1",
doi = "10.1007/s10549-018-4878-8",
language = "English",
volume = "171",
pages = "693--699",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York LLC",
number = "3",

}

TY - JOUR

T1 - Dosimetric study to assess the feasibility of intraoperative radiotherapy with electrons (ELIOT) as partial breast irradiation for patients with cardiac implantable electronic device (CIED)

AU - Luraschi, Rosa

AU - Lazzari, Roberta

AU - Galimberti, Viviana

AU - Rondi, Elena

AU - Bazani, Alessia

AU - Corso, Giovanni

AU - Colombo, Nicola

AU - Ricotti, Rosalinda

AU - Fodor, Cristiana

AU - Winnicki, Mikolaj

AU - Leonardi, Maria Cristina

AU - Jereczek-Fossa, Barbara Alicja

AU - Cattani, Federica

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Purpose: To report in-vivo dosimetry in the infraclavicular region, a potential site of a cardiac implantable electronic device (CIED) and to evaluate the absorbed dose from intraoperative radiotherapy with electrons (ELIOT). Methods: 27 non-cardiopathic breast cancer (BC) patients without CIED received quadrantectomy and ELIOT as partial breast irradiation. Before delivering ELIOT, two catheters, each containing eight thermoluminescent dosimeters (TLDs), were positioned in the infraclavicular region. TLDs internal catheter was located deep in the tumor bed while the external catheter was placed on patient’s skin. Results: Data were available for 24/27 patients. The absorbed doses were referred to the dose of 21 Gy. Values measured by the external catheter were low, although statistically significant higher doses were found close to the applicator (mean values 0.26–0.49 Gy). External TLD doses in proximity of the applicator were lower than those detected by their internal counterparts. Values measured by the internal catheter TLDs varied according to the distance from the applicator while no correlation with tumor site and beam energy was found. The distance from the applicator to deliver < 2 Gy to a CIED was 2 cm, while from 2.5 cm the dose measured in all the patients became negligible. Conclusions: This dosimetric study provided data to support the clinical use of ELIOT in BC patients having CIEDs as long as the suggested minimum safe distance of 2.5 cm is taken from the RT field in case of ELIOT single dose of 21 Gy, in the energy range of 6–10 MeV.

AB - Purpose: To report in-vivo dosimetry in the infraclavicular region, a potential site of a cardiac implantable electronic device (CIED) and to evaluate the absorbed dose from intraoperative radiotherapy with electrons (ELIOT). Methods: 27 non-cardiopathic breast cancer (BC) patients without CIED received quadrantectomy and ELIOT as partial breast irradiation. Before delivering ELIOT, two catheters, each containing eight thermoluminescent dosimeters (TLDs), were positioned in the infraclavicular region. TLDs internal catheter was located deep in the tumor bed while the external catheter was placed on patient’s skin. Results: Data were available for 24/27 patients. The absorbed doses were referred to the dose of 21 Gy. Values measured by the external catheter were low, although statistically significant higher doses were found close to the applicator (mean values 0.26–0.49 Gy). External TLD doses in proximity of the applicator were lower than those detected by their internal counterparts. Values measured by the internal catheter TLDs varied according to the distance from the applicator while no correlation with tumor site and beam energy was found. The distance from the applicator to deliver < 2 Gy to a CIED was 2 cm, while from 2.5 cm the dose measured in all the patients became negligible. Conclusions: This dosimetric study provided data to support the clinical use of ELIOT in BC patients having CIEDs as long as the suggested minimum safe distance of 2.5 cm is taken from the RT field in case of ELIOT single dose of 21 Gy, in the energy range of 6–10 MeV.

KW - Breast cancer

KW - Cardiac devices

KW - In vivo dosimetry

KW - Intraoperative radiotherapy

KW - Thermoluminescent dosimeters

UR - http://www.scopus.com/inward/record.url?scp=85049592468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049592468&partnerID=8YFLogxK

U2 - 10.1007/s10549-018-4878-8

DO - 10.1007/s10549-018-4878-8

M3 - Article

C2 - 29978418

AN - SCOPUS:85049592468

VL - 171

SP - 693

EP - 699

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -